Table 2. Multivariable analysis of characteristics of glioma patients divided according to TERT promoter mutations and the RTL (n = 330).

Characteristics	TERT promoter mutations						RTL
	Overall		C228T		C250T
	OR* (95% CI)	P	OR* (95% CI)	P	OR* (95% CI)	P	OR* (95% CI)	P
Gender	2.12 (1.26–3.56)	0.005	1.26 (0.67–2.36)	0.478	3.19 (1.51–6.75)	0.002	1.33 (0.83–2.14)	0.243
Age1	1.94 (1.00–3.76)	0.052	2.11 (0.96–4.64)	0.062	1.37 (0.55–3.42)	0.503	2.24 (1.09–4.60)	0.029
WHO grade2	1.81 (1.23–2.66)	0.003	1.52 (0.95–2.44)	0.083	1.80 (1.08–3.01)	0.025	0.95 (0.67–1.33)	0.751
Pathological diagnosis3	0.94 (0.72–1.22)	0.643	1.08 (0.79–1.47)	0.628	0.80 (0.55–1.17)	0.248	0.95 (0.74–1.22)	0.680
Recurrence	1.46 (0.79–2.70)	0.225	1.19 (0.56–2.54)	0.646	1.54 (0.67–3.57)	0.311	1.70 (1.00–2.89)	0.049
Seizures	1.52 (0.88–2.63)	0.133	0.99 (0.51–1.94)	0.980	2.13 (0.99–4.56)	0.052	1.23 (0.75–2.01)	0.417
KPS4	2.68 (1.50–4.80)	0.001	1.02 (0.51–2.04)	0.964	6.33 (2.73–14.71)	<0.001	1.32 (0.79–2.20)	0.289
IDH1 mutation	0.96 (0.55–1.71)	0.900	1.50 (0.76–2.98)	0.246	0.53 (0.24–1.20)	0.131	1.45 (0.86–2.45)	0.168
MGMT methylation	1.27 (0.74–2.18)	0.391	1.67 (0.84–3.30)	0.142	0.81 (0.39–1.70)	0.577	0.99 (0.60–1.61)	0.951
RTL	0.58 (0.34–1.01)	0.053	0.43 (0.22–0.82)	0.011	1.07 (0.49–2.32)	0.871	—	—

^*OR: odds ratio with 95% confidence interval;

¹Age (≥60; <60);

²WHO grade (I; II; III; IV);

³Pathological diagnosis (Diffuse astrocytoma; Oligodendroglioma; Oligoastrocytoma; Glioblastoma);

⁴KPS (≥80; <80).